Optimization of the vancomycin administration regimen by clinical pharmacists based on a population pharmacokinetics model: a prospective interventional study

References

• Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835–864.
   PubMed Web of Science ®Google Scholar
• He N, Su S, Ye Z, et al. Evidence-based guideline for therapeutic drug monitoring of vancomycin: 2020 update by the division of therapeutic drug monitoring, Chinese Pharmacological Society. Clin Infect Dis. 2020;71(Suppl 4):S363–S71.
   PubMedGoogle Scholar
• Matsumoto K, Oda K, Shoji K, et al. Clinical practice guidelines for therapeutic drug monitoring of vancomycin in the framework of Model-Informed precision dosing: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Pharmaceutics. 2022;14(3):489.
   PubMed Web of Science ®Google Scholar
• Zhu J, Jiang L. Monitoring and analysis of trough concentration of vancomycin in hospitalized patients in a tertiary hospital from 2015 to 2016. Zhonghua Nei ke za Zhi. 2021;60(2):147–149.
   PubMedGoogle Scholar
• Bakke V, Sporsem H, Von der Lippe E, et al. Vancomycin levels are frequently subtherapeutic in critically ill patients: a prospective observational study. Acta Anaesthesiol Scand. 2017;61(6):627–635.
   PubMed Web of Science ®Google Scholar
• Carland JE, Stocker SL, Baysari MT, et al. Are vancomycin dosing guidelines followed? A mixed methods study of vancomycin prescribing practices. Br J Clin Pharmacol. 2021;87(11):4221–4229.
   PubMed Web of Science ®Google Scholar
• Tang L, Yan X, Peng Q, et al. Analysis of therapeutic drug monitoring and clinical efficacy of vancomycin in patients with augmented renal clearance. Chin Hosp Pharm J. 2018;38(15):1629–1632.
   Google Scholar
• Broeker A, Nardecchia M, Klinker K, et al. Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting. Clin Microbiol Infection. 2019;25(10):1286. e1–e7.
   Web of Science ®Google Scholar
• Hughes DM, Goswami S, Keizer RJ, et al. Bayesian clinical decision support-guided versus clinician-guided vancomycin dosing in attainment of targeted pharmacokinetic parameters in a paediatric population. J Antimicrob Chemother. 2020;75(2):434–437.
   PubMed Web of Science ®Google Scholar
• Frymoyer A, Schwenk HT, Zorn Y, et al. Model-informed precision dosing of vancomycin in hospitalized children: Implementation and adoption at an academic Children's Hospital. Front Pharmacol. 2020;11:551. (
   PubMed Web of Science ®Google Scholar
• Kufel WD, Seabury RW, Mogle BT, et al. Readiness to implement vancomycin monitoring based on area under the concentration-time curve: A cross-sectional survey of a national health consortium . Am J Health Syst Pharm. 2019;76(12):889–894.
   PubMed Web of Science ®Google Scholar
• Buelga DS, del Mar Fernandez de Gatta M, Herrera EV, et al. Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies. Antimicrob Agents Chemother. 2005;49(12):4934–4941.
   PubMed Web of Science ®Google Scholar
• Keita H, Hidetoshi I, Takayuki S, et al. Augmented renal clearance in patients with febrile neutropenia is associated with increased risk for subtherapeutic concentrations of vancomycin. Ther Drug Monit. 2016;38(6):706–710.
   Google Scholar
• Fang J, Liu LY, Huang J, et al. Study on the optimization of dosage regimen of vancomycin. Pcar. 2017;17(3):179–182.
   Google Scholar
• Shi Y, He J, Mao E, et al. Study on the optimization of administration regimen of vancomycin in critical patients. Zhonghua Wei Zhong Bing ji Jiu yi Xue. 2020;32(2):140–144.
   PubMedGoogle Scholar
• Wang N, Chen CQ, Huang J, et al. Optimizing vancomycin dosage for severely infected patients based on population pharmacokinetics software. Clin Pharmac. 2020;29(16):47–50.
   Google Scholar
• Yu YX, Lu J, Lu HD, et al. Predictive performance of reported vancomycin population pharmacokinetic model in patients with different renal function status, especially those with augmented renal clearance. Eur J Hosp Pharm. 2022;29(e1):e6–e14.
   PubMedGoogle Scholar
• Han L, Xu F, Zhang X, et al. Predictive performance of smart dose, PharmVan and JPKD on vancomycin plasma concentration. Zhonghua Wei Zhong Bing ji Jiu yi Xue. 2021;33(3):263–268.
   PubMedGoogle Scholar
• He Z, Wu J, Qiu K. Guideline for clinical pharmacist on individual administration of vancomycin. Pharm Today. 2015;25(2):78–82.
   Google Scholar
• Ye Z, Chen Y, Chen K, et al. Therapeutic drug monitoring of vancomycin: a guideline of the division of therapeutic drug monitoring, Chinese Pharmacological Society. J Antimicrob Chemother. 2016;71(11):3020–3025.
   PubMed Web of Science ®Google Scholar
• Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharmaceut. 1981;9(4):503–512.
   PubMedGoogle Scholar
• Chen Y, Wu D, Dong M, et al. Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants. Eur J Clin Pharmacol. 2018;74(7):921–930.
   PubMed Web of Science ®Google Scholar
• van der Meer AF, Marcus MA, Touw DJ, et al. Optimal sampling strategy development methodology using maximum a posteriori Bayesian estimation. Therapeut Drug Monitor. 2011;33(2):133–146.
   PubMed Web of Science ®Google Scholar
• He J, Yang W. Establishment of the individualized drug delivery model of vancomycin for infected patients based on population pharmacokinetics and its clinical application. Chin J Clin Pharm. 2015;24(1):27–31.
   Google Scholar
• Šíma M, Bakhouche H, Hartinger J, et al. Therapeutic drug monitoring of antibiotic agents: evaluation of predictive performance. Eur J Hosp Pharm. 2019;26(2):85–88.
   PubMedGoogle Scholar
• Writing Group of Guidance for Clinical Trials of Anti-bacterial Drugs. Guidance for clinical trials of anti-bacterial drugs. Chin J Clin Pharmacol. 2014;30(9):844–856.
   Google Scholar
• Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179–c184.
   PubMedGoogle Scholar
• Morrison AP, Melanson SEF, Carty MG, et al. What Proportion of vancomycin trough levels are drawn too early? Am J Clin Pathol. 2012;137(3):472–478.
   PubMed Web of Science ®Google Scholar
• Xu G, Chen E, Mao E, et al. Research of optimal dosing regimens and therapeutic drug monitoring for vancomycin by clinical pharmacists: analysis of 7-year data. Chin Crit Care Med. 2018;30(7):640–645.
   Google Scholar
• Abdul-Aziz MH, Alffenaar J-WC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intens Care Med. 2020;46(6):1127–1153.
   PubMed Web of Science ®Google Scholar
• Phillips CJ, McKinnon RA, Woodman RJ, et al. Sustained improvement in vancomycin dosing and monitoring post-implementation of guidelines: results of a three-year follow-up after a multifaceted intervention in an Australian teaching hospital. J Infect Chemother. 2018;24(2):103–109.
   PubMed Web of Science ®Google Scholar
• Golenia BS, Levine AR, Moawad IM, et al. Evaluation of a vancomycin dosing nomogram based on the modification of diet in renal disease equation in intensive care unit patients. J Crit Care. 2013;28(5):710–716.
   PubMed Web of Science ®Google Scholar